Ozempic has made GLP-1 part of everyday health language. Peptides, once mostly discussed inside endocrinology circles, are now part of a public conversation about metabolism, appetite and long-term health. And those conversations are extending into the field of neurodegeneration, where Alzheimer’s and Parkinson’s are increasingly linked to impaired glucose metabolism, insulin signaling, neuroinflammation and neuronal energy use.
Danish biotech firm, Kariya Pharmaceuticals is advancing KP405, a brain-penetrant dual GLP-1/GIP agonist, toward Phase II testing in Parkinson’s and Alzheimer’s disease. In a recently-announced partnership, Israel-based NeuraLight is joining Kariya’s program as a biomarker partner, integrating its vision-based measurement platform into the trail. The partnership connects a next-generation GLP-1 therapeutic program with biomarker tools that increasingly show value in derisking and advancing CNS drug trails.
Peptides are short chains of amino acids, the same building blocks that make up proteins. Many hormones and signaling molecules in the body are peptide-based, including GLP-1, a hormone involved in glucose regulation, appetite and insulin release. GLP-1 receptor agonists activate that pathway, which is why drugs such as semaglutide (e.g. Ozempic), liraglutide and exenatide became important in treating diabetes and obesity by suppressing appetite.
Their relevance to brain disease starts with the link between metabolic dysfunction and neurodegeneration. Alzheimer’s and Parkinson’s are increasingly linked to impaired glucose metabolism, altered insulin signaling, neuroinflammation and reduced neuronal resilience. The GLP-1 thesis is that acting on these pathways may help restore aspects of cellular energy use, reduce inflammatory stress and support neuronal survival.
That hypothesis is currently undergoing clinical testing. The strongest result so far comes from the LIXIPARK trial, a Phase II trial of lixisenatide in people with early Parkinson’s disease. Lixisenatide is a GLP-1 receptor agonist currently used in type 2 diabetes. In the trial, patients receiving lixisenatide showed less progression of motor disability than those receiving placebo over 12 months.
In Alzheimer’s, the picture has been more mixed. ELAD, a Phase IIb trial of liraglutide in mild to moderate Alzheimer’s disease, did not meet its primary endpoint on cerebral glucose metabolism, although it reported signals on executive function and brain volume. Larger trials have since added caution, with semaglutide in Alzheimer’s and exenatide in Parkinson’s missing major endpoints. For Kariya and NeuraLight, those failures result from the fact that neither drug was designed specifically to cross the blood-brain barrier.
On May 14, Kariya and NeuraLight announced a partnership to integrate NeuraLight’s biomarker platform into Kariya’s Phase II program for KP405, a brain-penetrant dual GLP-1/GIP receptor agonist in development for Parkinson’s and Alzheimer’s disease. Kariya has positioned KP405 as a next-generation GLP-1 program, with engineered brain delivery as the central distinction from earlier metabolic GLP-1 drugs.
The partnership is built around one of the main problems making neurodegenerative drug development risky and expensive. Symptomatic trials can be judged by whether patients improve on established measures. But neurodegenerative trials are more opaque, as the aim is to preserve function in vulnerable circuits over long stretches of time. In Parkinson’s and Alzheimer’s, where progression is slow and heterogeneous, clinical scales may capture downstream symptoms only after underlying brain function has already changed.
NeuraLight’s platform is designed to address that gap through vision-based biomarkers. The system measures brain function by having patients perform visual tasks while eye-movement patterns are captured and analysed. Eitan Raveh, NeuraLight’s VP of Clinical Partnerships, explains, “Distinct patterns of eye movement abnormalities are controlled by well-mapped neural circuits, and by accurately capturing the change in these patterns, the platform provides objective, quantitative biomarkers of brain dysfunction.”
The oculomotor system gives that approach its neurological basis. “Few systems in the brain are as neurologically rich as the oculomotor system,” Raveh says. Eye movements draw on the basal ganglia, cerebellum, brainstem, frontal cortex and thalamus, which gives them relevance across several neurological pathways. In Parkinson’s disease, NeuraLight points to oculomotor abnormalities as a strong reflection of basal ganglia dysfunction.
For Kariya’s Phase II program, the platform will be used to assess whether KP405’s proposed mechanism translates into measurable functional preservation. Raveh explains, “KP405 is designed to penetrate the brain and activate complementary receptor pathways that reduce neuroinflammation and protect neurons. NeuraLight's biomarkers provide a direct measure of whether that translates to functional preservation across the trial.”
NeuraLight sits in a developing category of neurotech companies building measurement infrastructure for pharma. Raveh frames the value of this infrastructure directly, “When a trial fails, it is often impossible to know whether the drug didn't work, or whether the endpoint simply wasn't sensitive enough to see it.” For GLP-1s in neurodegeneration, that look inside might be the key to turning a popular class of metabolic drugs into a tool for preserving brain function.
.svg)
